Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis
Abstract Background The introduction of Direct-Acting Antivirals (DAAs) transformed Hepatitis C (HCV) treatment, despite this uptake of DAAs remains lower than required to meet the WHO Sustainable Development Goal (3.3). Treatment with interferon was suggested to be able to deliver important outcome...
Saved in:
Main Authors: | Sarah R. Donaldson, Andrew Radley, John F. Dillon |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Harm Reduction Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12954-024-01142-3 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents
by: Zhang Y, et al.
Published: (2025-01-01) -
NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
by: M. V. Mayevskaya, et al.
Published: (2015-12-01) -
Residual HCV-RNA and Elevated Platelet-to-Lymphocyte Ratio Predict Poor Long-Term Outcomes in Patients with Chronic Hepatitis C After Treatment
by: Anna Wróblewska, et al.
Published: (2024-12-01) -
Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients
by: Juferdy Kurniawan, et al.
Published: (2024-10-01) -
Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
by: T. Berg, et al.
Published: (2019-01-01)